PlasmaGen Biosciences
PlasmaGen Biosciences is India's first pure-play plasma biopharma company, manufacturing plasma-derived therapeutics including albumin, IVIG, and rabies immunoglobulin for hospitals and physicians across India and pursuing international expansion.
- Company typePrivate
- Founded2010
- HeadquartersBangalore, India
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What PlasmaGen Biosciences does
PlasmaGen Biosciences is a Bengaluru-headquartered biopharmaceutical company founded in 2010, operating as India's first pure-play plasma biopharma player. The company develops, manufactures, and distributes blood plasma-derived therapeutic products including albumin, intravenous immunoglobulin (IVIG), and rabies immunoglobulin. Production is enabled by a plasma fractionation and purification facility in Kolar, Karnataka, which commenced commercial operations in late 2023/2024, making it one of only five such facilities in India.
The company's core technology centers on end-to-end plasma fractionation processes, transforming human blood plasma into finished biological therapeutics used in the treatment of immune disorders, neurological conditions, hematological disorders, and rabies exposure. This vertically integrated capability addresses India's structural demand-supply gap for plasma-derived therapies and reduces reliance on imported biologics.
PlasmaGen operates a B2B enterprise sales model, distributing products directly to hospitals, clinics, and physicians across more than 70 Indian cities, reaching over 5,000 healthcare providers. Revenue is generated through pharmaceutical product sales to healthcare institutions. The company is pursuing international expansion by leveraging identified distribution partners in target export markets and securing the requisite regulatory approvals. Cumulative funding exceeds Rs 600 crore (~$68M) from investors including Eight Roads Ventures, Fidelity's FIL Capital Investments, F-Prime Capital, and ViNS Bioproducts, with a post-money valuation of over Rs 1,500 crore (~$170M) following the December 2025 funding round.
PlasmaGen Biosciences firmographics
Firmographics- Name
- PlasmaGen Biosciences
- Legal name
- PlasmaGen Biosciences
- Website
- https://plasmagen.in
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- PlasmaGen Biosciences is India's first pure-play plasma biopharma company, manufacturing plasma-derived therapeutics including albumin, IVIG, and rabies immunoglobulin for hospitals and physicians across India and pursuing international expansion.
- Ownership category
- akta.pro rank
PlasmaGen Biosciences industry classification
Industry- Product category
- Plasma-derived Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Plasma Fractionation & Purification Manufacturing (HLAIAHAI)
- akta.pro secondary industries
- Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Plasma-Derived & Blood Products Distributors (HLAIAJAJ), Plasma-Derived Therapy Cold Chain & Specialty Logistics (HLAIAHAL)
Keywords
Where PlasmaGen Biosciences is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
PlasmaGen Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel
Revenue model
- Plasma-derived Therapeutics Sales: Revenue generated from manufacturing and selling plasma-derived biological products including albumin, intravenous immunoglobulin (IVIG), and rabies immunoglobulin to healthcare providers and institutions.
- International Market Expansion: Future revenue stream from exports of plasma-derived therapies to international markets following regulatory approvals, with identified distribution partners.
Go-to-market motion2 records
Distribution channels2 records
PlasmaGen Biosciences product offering
Product offeringCore offering
PlasmaGen Biosciences manufactures and distributes blood plasma-derived therapeutic products, including albumin, intravenous immunoglobulin (IVIG), and rabies immunoglobulin, produced through plasma fractionation at its Kolar, Karnataka facility. The company is India's first pure-play plasma biopharma player and supplies these biological therapies to hospitals, physicians, and healthcare institutions across India, with planned international exports through distribution partners.
Product overview
PlasmaGen Biosciences operates as a biopharmaceutical company specializing in plasma-derived therapies. The company offers a portfolio of blood plasma-derived products including albumin, intravenous immunoglobulin (IVIG), and rabies immunoglobulin, all manufactured at its plasma fractionation facility in Kolar, Karnataka. The products are distributed across over 70 Indian cities covering more than 5,000 physicians and hospitals. The company is positioning itself to expand internationally through regulatory approvals for exports.
Differentiator
Problem solved
Functional benefit
Products and services
- Albumin Plasma-derived albumin product manufactured through plasma fractionation at PlasmaGen's Kolar, Karnataka facility, used for medical treatments including volume replacement, shock management, and other therapeutic applications. Sold to hospitals, clinics, and physicians across India.
- Intravenous Immunoglobulin (IVIG) Plasma-derived intravenous immunoglobulin (IVIG) product manufactured through plasma fractionation, used for treating immunological disorders and immune deficiencies in hospital and clinical settings. Distributed to healthcare providers across 70+ Indian cities.
- Rabies Immunoglobulin Plasma-derived rabies immunoglobulin product manufactured through plasma fractionation at PlasmaGen's Kolar facility, used for post-exposure prophylaxis against rabies infection. Sold to hospitals and healthcare providers across India.
Quantifiable outcome
- Valuation exceeded Rs 1,500 crore following December 2025 funding round
Companies that use PlasmaGen Biosciences
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
PlasmaGen Biosciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PlasmaGen Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- International Distribution PartnersminorPlasmaGen has identified distribution partners in key export markets as part of its international expansion strategy. The company is pursuing regulatory approvals in these markets while leveraging these partners for market entry of its plasma-derived therapeutics.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
PlasmaGen Biosciences competitors and assessment
Company assessmentBroad incumbents
- CSL Behring: CSL Behring is the global leader in plasma-derived therapeutics, producing albumin, IVIG, and specialty coagulation factors from a worldwide fractionation network. It is the most direct global competitor to PlasmaGen's product portfolio, with deep hospital relationships and integrated plasma collection infrastructure.
- Grifols: Grifols is one of the world's largest plasma fractionators with vertically integrated plasma collection centers, IVIG, albumin, and coagulation factor portfolios. It competes head-to-head with PlasmaGen on product categories and would be a natural reference point for any international market entry.
- Takeda Pharmaceutical Company: Through its acquisition of Shire/Baxalta, Takeda operates a major plasma-derived therapy franchise (immunoglobulin, albumin, hemophilia products) with global manufacturing footprint. It is a relevant competitor particularly for specialty plasma products and international markets.
Direct peers
- Octapharma: Octapharma is a privately held global plasma fractionator producing human albumin, IVIG, and coagulation factors from plasma collected through its own centers. Its privately held structure and pure-play plasma focus make it the closest analogue to PlasmaGen's business model.
- Kedrion Biopharma: Kedrion is an Italy-headquartered pure-play plasma-derived therapy company producing albumin, IVIG, and coagulation factors with operations across Europe, the Americas, and Asia. Its geographic diversification and pure-play model closely mirror PlasmaGen's strategic intent.
- Bharat Serums and Vaccines: Bharat Serums and Vaccines is an India-based biopharmaceutical company with a plasma-derived therapy portfolio including equine and human rabies immunoglobulin, tetanus immunoglobulin, and other plasma products. It is the most direct domestic competitor to PlasmaGen in the Indian market.
- Reliance Life Sciences: Reliance Life Sciences is an Indian biopharmaceutical company with a plasma-derived therapy portfolio including albumin, IVIG, and other plasma fractions. As a domestic competitor with established Indian distribution, it directly contests PlasmaGen's home-market share.
Emerging players
- Intas Pharmaceuticals: Intas Pharmaceuticals is one of India's largest generic and biosimilar manufacturers with selected plasma-derived products and biosimilars in its portfolio. Its scale, domestic distribution, and growing biologics capabilities position it as an adjacent competitor for PlasmaGen's Indian market.
- Emergent BioSolutions: Emergent BioSolutions operates a plasma-derived therapy business (acquired from Cangene) producing hyperimmune globulins including rabies immunoglobulin. Its product overlap with PlasmaGen's rabies IG line and focus on specialty plasma therapeutics make it a relevant emerging peer.
Regional players
- Sanquin Plasma Products: Sanquin is the Netherlands-based nonprofit blood supply organization that operates plasma fractionation and produces plasma-derived therapies primarily for European markets. It is a peer in fractionation capability and serves as a model for nonprofit/government-affiliated plasma fractionation structures.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
PlasmaGen Biosciences social profiles
Digital presencePlasmaGen Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
PlasmaGen Biosciences leadership team
Management profileNumber of profiles
Profiles2 records
PlasmaGen Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PlasmaGen Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PlasmaGen Biosciences
What does PlasmaGen Biosciences do?
PlasmaGen Biosciences manufactures and distributes blood plasma-derived therapeutic products, including albumin, intravenous immunoglobulin (IVIG), and rabies immunoglobulin, produced through plasma fractionation at its Kolar, Karnataka facility. The company is India's first pure-play plasma biopharma player and supplies these biological therapies to hospitals, physicians, and healthcare institutions across India, with planned international exports through distribution partners.
Is PlasmaGen Biosciences a public or private company?
PlasmaGen Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was PlasmaGen Biosciences founded?
PlasmaGen Biosciences was founded in 2010. It employs 251 to 500 people.
Where is PlasmaGen Biosciences based?
PlasmaGen Biosciences is headquartered in Bangalore, India, in the Asia region.
How does PlasmaGen Biosciences make money?
Two revenue lines are on record. Plasma-derived Therapeutics Sales are the primary driver. The others are international Market Expansion.
Who are PlasmaGen Biosciences's main competitors?
Broad incumbents on record are CSL Behring, Grifols and Takeda Pharmaceutical Company. Direct peers are Octapharma, Kedrion Biopharma, Bharat Serums and Vaccines and Reliance Life Sciences. Emerging players are Intas Pharmaceuticals and Emergent BioSolutions. Sanquin Plasma Products is listed as a regional player.
Does PlasmaGen Biosciences have an API?
No public API is recorded for PlasmaGen Biosciences.
What industry is PlasmaGen Biosciences in?
PlasmaGen Biosciences's product category is Plasma-derived Biopharmaceuticals. Its primary akta.pro industry code is HLAIAHAI, Plasma Fractionation & Purification Manufacturing, with a secondary code of HLAAAEAH, Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins). Its NAICS code is 325414 and its SIC code is 2836.